In an historic move, Ukraine’s President Zelensky signed a new law on 13 February 2024, legalising the use of cannabis for medicinal, scientific research and industrial use.

This new legislation will prove transformative for millions of patients within the country who will benefit from medicinal cannabis, helping those suffering from cancer, chronic pain, severe illness and post-traumatic stress order (PTSD) which has, in more recent times, been aggravated by the trauma of the Russian invasion.  

The bill will come into force six months after the publication of the legislation and means that patients will be able to receive medicinal cannabis treatments in the second half of 2024. The ban on the recreational use of cannabis remains in place.

The law enables both the commercial importation of cannabis plant substances for pharmaceutical manufacturing and authorised cannabis-based medicines. Operating under strict regulations, GMP certified entities will be able to produce cannabis-based medicines. These will be monitored under 24-hour video surveillance, accessible to the National Police. Strict regulatory requirements will have to be met for licencing, cultivation, manufacturing, storage and distribution, traceability and security requirements.

Oximio, Ukraine – Assisting Medical Cannabis Research

Established in 2004, Oximio, Ukraine, has been delivering end-to-end clinical trial supply chain solutions for nearly two decades. Offering tailored solutions stretching across customs clearance and IOR, regulatory requirements and licenced warehouse storage and distribution services, we are exceptionally well placed to handle the rigid requirements relating to the management and handling of medical cannabis. To find out how we can support your clinical trial, please contact us.